Maya Aji, APRN
Primary Care · Plano, TXNPI 1841904364
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 244 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,373, 2.1 times the $1,124 reported in 2023. Among primary care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $22.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$920
- Sanofi$480
- Merck$365
- Mallinckrodt Hospital Products Inc.$334
- AOP Health US, LLC$272
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,48098%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 46 | $1,142 |
| GSK | 60 | $920 |
| Sanofi | 16 | $480 |
| Merck | 14 | $365 |
| Mallinckrodt Hospital Products Inc. | 16 | $334 |
| AOP Health US, LLC | 1 | $272 |
| Baxter Healthcare | 11 | $225 |
| Grifols USA, LLC | 9 | $212 |
| Regeneron Healthcare Solutions, Inc. | 5 | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $148 |
| Lilly USA, LLC | 3 | $147 |
| Viatris Specialty LLC | 7 | $147 |
| Electromed, Inc. | 8 | $140 |
| United Therapeutics Corporation | 4 | $115 |
| Johnson & Johnson | 5 | $100 |
| Boehringer Ingelheim | 5 | $100 |
| ANI Pharmaceuticals, Inc. | 3 | $79 |
| AbbVie | 3 | $77 |
| Mylan Specialty L.p. | 3 | $68 |
| Insmed, Inc. | 3 | $66 |
| Philips North America LLC | 4 | $58 |
| Actelion Pharmaceuticals US, Inc. | 2 | $45 |
| Inogen, Inc. | 2 | $29 |
| Liquidia Technologies, Inc. | 1 | $29 |
| Optinose US, Inc. | 1 | $28 |
| Pfizer | 1 | $27 |
| Tactile Systems Technology Inc | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Breas Medical, Inc. | 1 | $16 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,580 in reported general payments places this provider in the 95th percentile of 563 primary care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 155 | $125,925 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $19,776 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $17,124 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $8,340 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $6,996 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $6,469 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 151 | $3,786 |
| BreynaBudesonide/Formoterol Fumarate | 17 | $3,572 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $3,363 |
| Roflumilast | 27 | $1,454 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 23 | $1,427 |
| Fluticasone Propionate | 63 | $1,315 |
| Montelukast Sodium | 72 | $939 |
| Ventolin HfaAlbuterol Sulfate | 11 | $838 |
| Prednisone | 145 | $420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $920 | $143,048190 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,142 | $26,77256 claims |
| Boehringer IngelheimCombivent Respimat, Stiolto Respimat | $100 | $14,80928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 563 primary care providers in Texas.
Other primary care in Plano
- Mary GibbensHouston$42K
- Phillip GulleySan Antonio$23K
- Herbert BautistaDallas$14K
- Brandi JoynerLongview$12K
- Steven ParisAustin$10K
- Hope OdomCollege Station$10K
- Arlena GraysTomball$9K
- Charlotte BallardSan Antonio$9K
- Hannah LancasterMcKinney$9K
- Jacqueline MilesGrand Prairie$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.